Brief: Theravance Biopharma, Inc. Announces Enrollment Of First Patient In Yupelri® Phase 4 Study
10/01/2022 11:39
Jan 10 (Reuters) - Theravance Biopharma Inc TBPH.O :
* THERAVANCE BIOPHARMA, INC. ANNOUNCES ENROLLMENT OF FIRST PATIENT IN
YUPELRI®
PHASE 4 STUDY
Source text for Eikon: ID:nPnbBnsqKa
Further company coverage: TBPH.O
Recent news on Theravance Biopharma
See all newsIreland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth
Ireland's Theravance Biopharma Q4 revenue misses expectations
Corrected: BRIEF-Theravance Biopharma Q4 Operating Income USD 20.012 Million
U.S. STOCKS ON THE MOVE-Versant Media Group, Lithium miners, Expedia Group
U.S. STOCKS ON THE MOVE-Expedia Group, Blue Owl Capital, Enphase Energy